0 UW0 25923 – – – – – – – – ® 20–26 27–35 21–26 27–31 26–34 29–35 25–32 20–28 23–29 25–34 22–28 24–33 25–31 17–23 23–29 19–25 27–33 26–35 16–20 27–35 22–28 27–35 29–37 19–26 20–27 aureus aureus ATCC Staphylococcus Staphylococcus DFDPRPELQDLRQJHQV β 0 7DEOH Antimicrobial Agents Excluding AgentsAntimicrobial 27853 –26 – – – – – – – – – – – – – – – – – – – – – – ® 24–30 23–29 18–24 25–31 22–31 23–29 18–22 22–29 12–17 17–23 20 aeruginosa aeruginosa ATCC Pseudomonas Pseudomonas Disk Diffusion QC Ranges, mm QCDisk Ranges, Diffusion 1RQIDVLGLRVLVNLIIVLRQ4(FOGLQJ

25922 – – b ® coli 19–26 15–22 28–36 23–29 23–27 26–32 21–27 24–28 22–28 31–37 24–29 25–31 20–26 26–32 25–29 28–34 29–35 28–34 23–29 23–28 21–27 26–34 25–32 27–35 30–36 29–35 20–26 15–21 21–27 26–32 25–31 Escherichia Escherichia ATCC for Nonfastidious Organisms and and Organisms for Nonfastidious

a g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g m m m m m m m m m m m m m m m m m m m m m m m m m m m m m

m m m m 5 5 5 5 5 30 10 15 75 30 30 30 30 30 10 30 30 30 75 30 30 30 10 30 30 30 30 30 30 30 30 30 100 100 Disk Content Disk

Agent Agent Antimicrobial -Lactam Combination Agents -Lactam Amikacin Azithromycin Ceftaroline Cephalothin Chloramphenicol Cinoxacin Table 4A-1. Disk Diffusion QC Disk Diffusion 4A-1. Ranges Table β

Licensed to: Juanita Smit This document is protected by copyright. CLSI order #Ord-615144,LLLL Downloaded on 1/13/2021. UW0 0

h d 40 25923 - ® 26–32 24–30 33–42 22–28 24–31 27–34 25–33 30–36 27–33 23–29 25–33 19–26 25–30 23–31 29–37 18–24 32 25–32 aureus ATCC Staphylococcus Staphylococcus DFDPRPELQDLRQJHQV β 0 7DEOH 32–39 d 29 27853 – – – – – – – – – 18–26 – 19–26 – 22–30 – – 24–32 – – 26–32 – 23–29 – – – 25–30 - ® 25–33 27–35 11–17 28–35 22–28 13–21 22–30 28–37 12–20 – 19–25 20–28 19–25 17–23 20–27 20–28 21–27 19–26 22–28 27–33 19–27 27–33 26–31 17–25 – 23–29 23 aeruginosa aeruginosa ATCC Pseudomonas Disk Diffusion QCmm Ranges, Diffusion Disk 1RQIDVLGLRVLVNLIIVLRQ4(FOGLQJ 17–23 d 25922 35 – – – – – – – - b ® coli 29–38 31–40 11–17 27–35 18–24 28–36 29–36 20–26 28–34 22–30 28–35 30–37 29–36 19–26 18–26 28–36 14–22 26–32 17–25 29–37 27–33 23–29 24–30 28–35 19–25 28–35 28 17–24 27–33 Escherichia ATCC g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g m m m m m m m m m m m m m m m m m m m m m m m m

m m m m m m m m m m m m 5 5 2 5 5 5 5 5 5 5 5 5 15 10 15 10 30 10 20 10 15 10 10 10 10 30 20 10 30 10 30 10 10 30 30 200 Disk Content Content Disk

c

d c

f e

Agent Agent g Antimicrobial Ciprofloxacin Clarithromycin Clinafloxacin Clindamycin Delafloxacin Dirithromycin Doxycycline Enoxacin Eravacycline Erythromycin Fleroxacin Fusidic acid Garenoxacin Gatifloxacin Gemifloxacin Gentamicin Gepotidacin Grepafloxacin Iclaprim Kanamycin Lefamulin Levofloxacin Levonadifloxacin Linezolid Lomefloxacin Minocycline Moxalactam 4A-1.Table (Continued)

Licensed to: Juanita Smit This document isLLLL protected by copyright. CLSI order #Ord-615144, Downloaded on 1/13/2021. 0 UW0

d h

25923 i – – – – ® 16–22 18–22 17–28 24–28 18–24 26–37 19–25 21–28 26–34 27–33 24–34 15–21 24–30 20–25 19–26 15–20 20–26 18–24 25–31 aureus aureus ATCC DFDPRPELQDLRQJHQV Staphylococcus Staphylococcus β 0 7DEOH 27853 – – – – – – – – – – – – – – – – 22–30 – – – – – – 22–30 – 14–22 – – – 24–30 24–32 17–21 ® 9–13 17–25 17–25 17–23 22–29 17–21 25–33 15–21 28–35 22–31 21–29 20–26 – 21–27 20–26 21–27 27–33 – 19–29 29–35 14–18 aeruginosa aeruginosa ATCC Pseudomonas Disk Diffusion QC Ranges, mm QC Diffusion Disk Ranges, 1RQIDVLGLRVLVNLIIVLRQ4(FOGLQJ

d 25922 – – – – – – – – – – b ® coli 8–10 28–35 28–35 22–28 22–30 20–25 29–33 22–28 25–33 24–30 21–27 13–19 21–26 30–38 12–20 15–23 30–37 18–25 24–30 20–27 18–26 21–28 23–29 10–16 29–36 32–38 24–30 Escherichia ATCC ction, control. QC, quality g g m m g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g m m m m m m m m m m m m m m m m m m m m

m m m m m m m m m m 2 µg 5 1 5 1 5 5 5 2 5 5 10 µg 10 µg 15 30 30 30 30 15 10 15 10 30 15 30 75 15 10 30 10 30 g or 300 300 g or 300 100 10 units 10 units m 300 units Disk Content Content Disk 1.25/23.75 250 , American Type Culture Colle Type , American ®

j

l

j

f j

g

Agent Agent k Antimicrobial Moxifloxacin Nafithromycin acidNalidixic Netilmicin Nitrofurantoin Norfloxacin Ofloxacin Omadacycline Pefloxacin Plazomicin B Quinupristin-dalfopristin Razupenem Rifampin Solithromycin Sparfloxacin Streptomycin Sulfisoxazole Sulopenem Tebipenem Tedizolid Telithromycin Tetracycline Tigecycline Tobramycin Trimethoprim Trimethoprim- sulfamethoxazole Trospectomycin Trovafloxacin Ulifloxacin (prulifloxacin) 4A-1.Table (Continued) Abbreviations: ATCC Abbreviations:

Licensed to: Juanita Smit This document is protected by copyright. CLSI order #Ord-615144,LLLL Downloaded on 1/13/2021. UW0 0

® ATCC S. aureus S. A-mediated erm the time of testing. time of the DFDPRPELQDLRQJHQV β used after “BAA” in each in used catalog each after “BAA” ibility testing. testing. ibility 0 7DEOH nded as supplemental QC strains (eg, forstrains(eg, QC supplemental as nded BAA-977™ (containinginducible BAA-977™ ® acturers were not available at at acturers were available not 25923 should be used for routine or used daily) for QC weekly should 25923be (eg, ® 29212 (gentamicin: 16–23 mm; streptomycin: 14–20 mm). mm; streptomycin:16–23 (gentamicin:29212 14–20 ® ATCC ATCC ATCC convention, trademark the issymbol ® Subchapter 3.1.1.2 for guidance, should a problem with QC problemQC foroccur.Subchapter should guidance, with a 3.1.1.2 S. aureus S. 1 1RQIDVLGLRVLVNLIIVLRQ4(FOGLQJ n should be used for antimicrobial suscept antimicrobial be n usedshould for S. aureus S.

E. faecalis E. 13th ed. CLSI standard M02. Clinical M02. 2018.and CLSI standard Standards 13th LaboratoryInstitute; Clinical ed. BAA-977™ should demonstrate inducible clindamycin resistance a positive should (ie,demonstrate inducible clindamycinBAA-977™ (ICR) Footnotes Footnotes ® 25923 should be read using transmitted read should light. 25923 be transmitted using ® g disks, use g ATCC m nufacturer. Disksnufacturer. other manuf from ATCC A-mediated macrolide-only efflux) are macrolide-only recomme efflux) A-mediated msr S. aureus S. S. aureus S. name. name. ® ican Type Culture Collection. Per ATCC Per Collection. Type Culture ican obial Disk Susceptibility Tests. Disk Susceptibility obial g of glucose-6-phosphate. g modified since edition.previous the 25923 can often produce the double or target zone phenomenon. For accurate QC results, use QC use phenomenon.results, For accurate target zone produce oftenor double can25923 the levelsthymidine See thymine.of M02, and m ® ormed with erythromycin and with erythromycinclindamycin, and ormed using standard Mueller-Hinton agar.standard using BAA-976™ should not demonstrate ICR. BAA-976™notdemonstrate should g and 300- gstreptomycin the prodrug prulifloxacin. Only ulifloxacithe prulifloxacin. prodrug ® m ATCC BAA-976™ (containing BAA-976™ ATCC -lactam combination agents. combination -lactam ® 700603 is a supplemental QC strain for testing QC of imipenem (25–33 mm) and tebipenem QC mm).(26–32 forisand700603 mm) oftesting QC a supplemental strain(25–33 imipenem tebipenem β ® ATCC S. aureus S. ATCC S. aureus S. r linezolid and tedizolid with with linezolidtedizolid and r 29212 is a supplemental QC strain toQCreading. foris29212tedizolid QC assist of mm)a supplemental (14–21 testing with strain ® S. aureus S.

ATCC g fosfomycin 50 disk contains g m is a registered trademark of thetrademark of Amer is a registered PerformanceStandards Antimicr for ® Information in boldface type is new ornew type in is Information boldface number,conjunction ATCC in registeredwith the andresistance) or test evaluation). assessment, training, competence whereastest), D-zone clindamycin erythromycin anddisksof Klebsiella pneumoniae 2921333–39 with mm.acceptable (no zones) double range faecalisE. CLSI.

. 1 4A-1.Table (Continued) a. Refer for4A-2Table QC to of b. ATCC c. tests perf approximation disk When are d. QC one rangesonly were ma disk using data from established e. The 200- f. For of 120- control ranges gentamicin g. ofh. fo inhibition Zones i. Razupenem with tested j. by be excess affected agents can These k l. the metabolite Ulifloxacin active of is NOTE: for Table Reference 4A-1

Licensed to: Juanita Smit This document isLLLL protected by copyright. CLSI order #Ord-615144, Downloaded on 1/13/2021.